<DOC>
	<DOCNO>NCT00702299</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving pemetrexed together cisplatin paclitaxel give different way may kill tumor cell . PURPOSE : This phase I trial study side effect best dose intraperitoneal pemetrexed give together intraperitoneal cisplatin paclitaxel treat patient stage III ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Alimta® Plus Cisplatin &amp; Paclitaxel Given Intraperitonelly ; First Line Tx Stage III Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose ( MTD ) combination therapy comprise intraperitoneal ( IP ) pemetrexed disodium combination IP cisplatin paclitaxel patient optimally debulked stage III ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer relation percentage patient complete least 6 course treatment . - To determine toxicity tolerability regimen patient . Secondary - To observe 80 % patient progression free 18 month initiation chemotherapy . - To determine , exploratory endpoint , median overall survival patient treat regimen . - To investigate pharmacokinetics regimen determine MTD patient . - To conduct correlative study tumor tissue blood patient . OUTLINE : This dose-escalation study pemetrexed disodium . Patients receive pemetrexed disodium intraperitoneally ( IP ) day 1 , cisplatin IP day 2 , paclitaxel IP day 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . At least 10 patient treat maximum-tolerated dose ( MTD ) . Whole blood sample tumor tissue specimen obtain patient baseline bank future DNA , RNA , protein study relate prediction disease progression treatment resistance . Plasma intraperitoneal fluid sample may also collect patient treat MTD pharmacokinetic analysis plasma concentration pemetrexed disodium high-performance liquid chromatography ( HPLC ) mass spectrometry-HPLC . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically pathologically confirm ovarian epithelial carcinoma , primary peritoneal carcinoma , fallopian tube carcinoma Stage III disease Meets 1 follow criterion : No prior treatment 6 month since primary surgery Platinumsensitive secondlook surgery prior cisplatin therapy Must optimally debulked le 2cm residual individual tumor plaque , suboptimally debulked first surgery , chemical debulking No mixed Müllerian tumor borderline ovarian tumor No Central nervous system ( CNS ) brain metastasis PATIENT CHARACTERISTICS : Gynecologic Oncology Group performance status 02 White blood cell count ( WBC ) ≥ 3,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Serum bilirubin ≤ 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time upper limit normal Creatinine clearance ≥ 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month discontinuation study drug No psychological , familial , sociological , geographical condition permit medical followup compliance study protocol No unstable preexist major medical condition , except cancerrelated abnormality No medical lifethreatening complication malignancies No know severe and/or uncontrolled concurrent medical disease ( e.g. , uncontrolled diabetes , uncontrolled chronic renal liver disease , active uncontrolled infection , HIV ) No serious active uncontrolled infection No inadequately control hypertension ( define systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg antihypertensive medication ) No New York Heart Association grade IIIV congestive heart failure No weight loss 5 ≤ 10 % within past 14 day relate ascites paracentesis No prior hypertensive crisis hypertensive encephalopathy No myocardial infarction , cerebrovascular accident , transient ischemic attack , unstable angina within past 6 month No evidence uncontrollable nausea No clinically significant symptomatic peripheral vascular disease ( e.g. , aortic aneurysm aortic dissection ) No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess No preexisting clinically significant hearing loss No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , cervical carcinoma situ , adequately treated stage I II cancer patient complete remission No known hypersensitivity component pemetrexed disodium Able take folic acid , vitamin B_12 , dexamethasone accord protocol No presence thirdspace fluid control drainage No inability comply study and/or followup procedure PRIOR CONCURRENT THERAPY : See Disease Characteristics May receive 4 course carboplatin paclitaxel IV neoadjuvant chemotherapy advance , unresectable disease Concurrent lowdose aspirin therapy ( i.e. , 325 mg/day ) allow Concurrent ibuprofen nonsteroidal antiinflammatory drug ( NSAIDs ) short elimination halflives allow provide ≥ 1 follow criterion meet : Creatinine clearance ( CrCl ) &gt; 80 mL/min ( i.e. , normal renal function ) CrCl 4579 mL/min ( i.e. , mild moderate renal insufficiency ) AND NSAID dosing interrupt period 2 day , , 2 day administration pemetrexed disodium Concurrent NSAIDs salicylates long halflives ( e.g. , naproxen , piroxicam , diflunisal , nabumetone ) allow provide NSAID dose interrupt least 5 day , , 2 day administration pemetrexed disodium No concurrent antineoplastic antitumor agent part study therapy ( i.e. , chemotherapy , radiotherapy , immunotherapy , hormonal anticancer therapy ) No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>